Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
Why Novo Nordisk Stock Just Popped
12:39pm, Monday, 09'th Feb 2026
Hims & Hers advertised a $49 Wegovy lookalike pill Thursday -- then on Saturday said it won't sell it. Both the FDA and Novo Nordisk have objected to what Hims & Hers is doing.
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
12:21pm, Monday, 09'th Feb 2026
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Hims & Hers Health Faces Legal and Regulatory Challenges, Stock Plummets
12:14pm, Monday, 09'th Feb 2026
Hims and Hers Health (HIMS) is experiencing a significant drop in stock value due to aggressive legal action and regulatory challenges. The telehealth provider is
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
12:04pm, Monday, 09'th Feb 2026
The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits t
HIMS Slides 25% After NVO Sues Company Over Generic GLP-1 Pills
11:00am, Monday, 09'th Feb 2026
Legal issues hits Hims & Hers (HIMS). Novo Nordisk (NVO) filed a lawsuit against the company over allegedly selling unapproved Wegovy and Ozempic weight loss drugs.
FDA says Novo's obesity pill TV Ad is false or misleading
10:59am, Monday, 09'th Feb 2026
The Food and Drug Administration said a television advertisement for Novo Nordisk's weight loss pill is "false or misleading", according to a letter dated February 5.
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
10:56am, Monday, 09'th Feb 2026
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
HIMS Stock Tumbles as FDA Scrutiny Boosts Novo Nordisk Shares
10:24am, Monday, 09'th Feb 2026
Hims and Hers (HIMS)stock dipped 15% on early Monday trading after halting sales of a $49 compounded semaglutide pill after regulators raised concerns.On the othe
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pills, injections
10:04am, Monday, 09'th Feb 2026
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker's new Wegovy obesity pill and injections in the U.S. CNBC'
Stock Market Today: Major Indexes Mixed After Volatile Week; Dow Slips Back Below 50000
10:00am, Monday, 09'th Feb 2026
Major stock indexes were mixed in early trading Monday after ending a volatile week with sharp gains.
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs
09:46am, Monday, 09'th Feb 2026
Novo Nordisk A/S (NYSE: NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE: HIMS) for infringing U.S. Patent 8,129,343 with Hims' compounded semaglutide produ
Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
09:27am, Monday, 09'th Feb 2026
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the fight between Novo Nordisk and Hims & Hers over GLP-1 drugs, immunization policies in the U.S., and more.
5 Things to Know Before the Stock Market Opens
08:56am, Monday, 09'th Feb 2026
Stock futures are slightly lower this morning after a Friday rally that pushed the Dow above 50,000 for the first time; investors are preparing for a big week of earnings reports and important economi
Novo Nordisk Surges as Hims & Hers Withdraws Weight-Loss Pill
07:39am, Monday, 09'th Feb 2026
Shares of Novo Nordisk (NVO, Financials) rose 8% after Hims and Hers Health decided not to sell a compounded form of semaglutide, the primary ingredient in the we
